Transdermal Scopolamine for Treatment-Resistant Major Depressive Disorder.

Conventional antidepressants are useful in the treatment of major depressive disorder (MDD) but are limited by their delayed onset of action and lack of adequate therapeutic response in approximately one-third of patients. This has led to a quest for faster-acting and more effective antidepressants. Scopolamine exhibits rapid antidepressant effects when administered intravenously. We report a case of a female with treatment-resistant depression (TRD) who responded to transdermal scopolamine. She had a rapid (within three days) and sustained (119 days) response to transdermal scopolamine. Further research into the use of transdermal scopolamine for the treatment of depression is recommended.

Informations de copyright

Copyright © 2024, Liester et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.